Abstracts Archive - Page 1890 of 2425 - ACR Meeting Abstracts

Abstract Number: 2445 • 2014 ACR/ARHP Annual Meeting
A Distinct Profile of Circulating Microparticles Is Associated with Disease Features in Rheumatoid Arthritis Patients and Impairs Endothelial Functionality in Vitro
Javier Rodríguez-Carrio¹, Mercedes Alperi-López², Patricia López¹, Sara Alonso-Castro², Santiago Rubén Carro-Esteban¹, Javier Ballina-García² and Ana Suárez¹, ¹Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ²Rheumatology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
Background/Purpose Cell-derived microparticles (MPs) could be considered biomarkers of cell damage and activation and they are thought to have a role in cardiovascular (CV) and inflammatory…
Abstract Number: 2446 • 2014 ACR/ARHP Annual Meeting
DNA Methylation Profiles That Distinguish Rheumatoid Arthritis from Osteoarthritis in Fibroblast-like Synoviocytes Can be Detected in Immune Cells from Peripheral Blood
Brooke Rhead¹, Calliope Holingue², Michael Cole², Xiaorong Shao², Hong L. Quach³, Diana Quach³, Lisa F. Barcellos³ and Lindsey A. Criswell⁴, ¹Genetic Epidemiology and Genomics Laboratory, Division of Epidemiology, University of California, Berkeley, Berkeley, CA, ²Genetic Epidemiology and Genomics Lab, Division of Epidemiology, University of California, Berkeley, Berkeley, CA, ³Epidemiology, University of California, Berkeley, Berkeley, CA, ⁴Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease with potential to cause substantial disability, primarily due to the erosive and deforming process in joints.…
Abstract Number: 2447 • 2014 ACR/ARHP Annual Meeting
The Role of TET3-Mediated DNA Demethylation By Pro-Inflammatory Cytokines in Rheumatoid Arthritis
Kazuhisa Nakano¹, Kunihiro Yamaoka¹, Akira Kurozumi², Akio Kawabe², Kaoru Yamagata² and Yoshiya Tanaka³, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The first department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose In the pathogenesis of Rheumatoid arthritis (RA) RA fibroblast-like synoviocytes (RA FLS) exhibit a unique aggressive phenotype that contributes to the cytokine milieu and…
Abstract Number: 2448 • 2014 ACR/ARHP Annual Meeting
DNA Methylation Analysis of Lymph Node Stromal Cells of Rheumatoid Arthritis Patients
Emmanuel Karouzakis¹, Caroline Ospelt¹, Janine Hähnlein², Renate E. Gay³, Paul Peter Tak⁴, Danielle Marie Gerlag⁵, Michel Neidhart¹, Steffen Gay¹ and Lisa G.M. van Baarsen², ¹Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland, ⁴University of Cambridge,Cambridge and GlaxoSmithKline, Stevenage, United Kingdom, ⁵GSK,Clinical Unit Cambridge,R&D Projects Clinical Platforms & Sciences, Cambridge, United Kingdom
Background/Purpose Lymph node stromal cells (LNSC) build the scaffold that enables migration and interaction of lymphocytes in the lymph node. More recently, it has been…
Abstract Number: 2449 • 2014 ACR/ARHP Annual Meeting
Microrna-346 Regulation of Follicular Helper T Cells Is Involved in the Pathogenesis of rheumatoid Arthritis Disease
Xinyi Tang¹, Jie Ma² and Shengjun Wang³, ¹Department of Laboratory Medicine, Jiangsu University Affi�liated People’s Hospital, Zhenjiang, China, ²Department of Laboratory Medicine, Jiangsu University Afﬁliated People’s Hospital, Zhenjiang, China, ³Department of Laboratory Medicine, Jiangsu University Affiliated People’s Hospital, Zhenjiang, China
Background/Purpose Follicular helper T (Tfh) cells have been identified as a new subset of effector helper T cells that are essential in regulating the development…
Abstract Number: 2450 • 2014 ACR/ARHP Annual Meeting
Downregulation of Mirna-196a and Its Downstream HOXC8 Target Gene in Rheumatoid Arthritis Synovial Fibroblasts
Maria Filkova¹, Michelle Trenkmann¹, Borbala Aradi-Vegh¹, Lenka Pleštilová¹, Joanna Stanczyk¹, Beat A. Michel², Ladislav Senolt³, Renate Gay¹, Steffen Gay⁴ and Astrid Juengel¹, ¹Center of Experimental Rheumatology, University Hospital Zurich, Zurich Schlieren, Switzerland, ²Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁴Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose Comprehensive analysis of 260 miRNAs suggested a downregulation of miR-196a in rheumatoid arthritis (RA) synovial fibroblasts (SF) compared with osteoarthritis (OA) SF. Mature miR-196a…
Abstract Number: 2451 • 2014 ACR/ARHP Annual Meeting
Mir-155 Expression Correlates with Clinical Disease Activity and Has Effector Function in Rheumatoid Arthritis
Aziza Elmesmari¹, Derek G. Gilchrist², Mariola Kurowska-Stolarska³ and Iain B. McInnes⁴, ¹Immunology, Institute of Infection,Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: MicroRNAs are fine tuners of biological pathways that function via post-transcriptional regulation of target mRNA life span. MicroRNA 155 (miR155) is particularly implicated in…
Abstract Number: 2452 • 2014 ACR/ARHP Annual Meeting
Protective Effect of the IL33 rs3939286 Gene Polymorphism in the Development of Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis
Raquel López-Mejías¹, Fernanda Genre¹, Mercedes García-Bermúdez², Alfonso Corrales¹, Carlos González-Juanatey³, Begoña Ubilla¹, J. Llorca⁴, Encarnación Amigo⁵, Jose A. Miranda-Filloy⁶, Trinitario Pina Murcia¹, Ricardo Blanco⁷, Santos Castañeda⁸, Javier Martin⁹ and Miguel A González-Gay¹, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ²Immunology and Cellular Biology, Instituto de Parasitologia y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ³Hospital Universitario Lucus Augusti. Cardiology Division, Lugo, Spain, ⁴Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁵Hospital Universitario Lucus Augusti, Rheumatology Division, Lugo, Spain, ⁶Rheumatology, Division of Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ⁷Hospital Marques de Valdecilla, Santander, Spain, ⁸Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, ⁹Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain
Background/Purpose: Rheumatoid arthritis (RA) is a complex inflammatory disease characterized by chronic inflammation, accelerated atherosclerosis and increased cardiovascular (CV) mortality. Interleukin 33 (IL-33) is a…
Abstract Number: 2413 • 2014 ACR/ARHP Annual Meeting
Similar Response Rates to Anti-Tumor Necrosis Factor and Non- Anti-Tumor Necrosis Factor Biologic Therapies in Ethnic Minority Patients at 6 Months
Gail S. Kerr¹, Yusuf Yazici², Christopher Swearingen³, Luis R. Espinoza⁴, Edward L. Treadwell⁵, Yvonne Sherrer⁶, Angelia Mosley-WIlliams⁷, Ignacio Garcia-Valladares⁸, Rodolfo Perez Alamino⁹, Sharon Dowell¹⁰, Mercedes Quinones¹¹, Akgun Ince¹², Theresa Lawrence Ford¹³, Chunqiao Luo¹⁴, Adrian Godoy¹⁰ and John Amatruda¹⁵, ¹Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Pediatrics and Biostatistics, University of Arkansas, Little Rock, AR, ⁴Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA, ⁵Dept Medicine Div of Rheum, East Carolina University, Greenville, NC, ⁶Rheum/Immunology, Centre Rheum Immunol Arthritis, Fort Lauderdale, FL, ⁷Rheumatology, Detroit VAMC, Detroit, MI, ⁸Immunology and Rheumatology, Hospital General de Occidente, Zapopan, Jal., Mexico, ⁹internal Medicine, LSUHSC, New Orleans, LA, ¹⁰Division of Rheumatology, Howard University, Washington, DC, ¹¹Division of Rheumatology, Howard University Hospital, Washington, DC, ¹²Arthitis Consultants Inc, St. Louis University, St. Louis, MO, ¹³North Georgia Rheumatology Group, PC, Lawrenceville, GA, ¹⁴University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁵Rheumatology, Howard University, Washington, DC
Similar Response Rates to Anti-Tumor Necrosis Factor and Non- Anti-Tumor Necrosis Factor Biologic Therapies in Ethnic Minority Patients Background/Purpose: Biologic therapies have expanded the treatment…
Abstract Number: 2414 • 2014 ACR/ARHP Annual Meeting
Etanercept in Mono Therapy or in Combination with MTX: Results from a Sub Analysis of a German Non-Interventional Study
Karl Heinz Goettl¹, Markus Gaubitz², Andreas Krause³, Udo Lendl⁴, Ralph Lippe⁴, Thomas Meng⁴ and Peter-Andreas Loeschmann⁵, ¹Joint practice for internal medicine, Passau, Germany, ²Academy of manual diagnostic at University of Münster, Münster, Germany, ³Konigstr. 63, Immanuel Krankenhaus Berlin, Berlin, Germany, ⁴Pfizer Pharma GmbH, Berlin, Germany, ⁵Loeschmann, Berlin, Germany
Background/Purpose Although a combination with MTX is recommended for all biologics, data from different registries around the world show that in real life around 30%…
Abstract Number: 2415 • 2014 ACR/ARHP Annual Meeting
Characteristics of Rheumatoid Arthritis Patients Not Receiving Early Initiation of Disease Modifying Therapy
Dimitrios A. Pappas^1,2, Jeffery D. Kent³, Jeffrey D. Greenberg^2,4, Marc Mason², Joel M. Kremer⁵, Amy Y. Grahn³ and Robert J. Holt⁶, ¹Columbia University, New York, NY, ²Corrona, LLC., Southborough, MA, ³Horizon Pharma, Inc., Deerfield, IL, ⁴Rheumatology, New York University School of Medicine, New York, NY, ⁵Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁶University of Illinois - Chicago, Chicago, IL
Background/Purpose : Early and aggressive therapy of Rheumatoid Arthritis (RA) with Disease Modifying Anti-Rheumatic Agents (DMARDs), glucocorticoids, and biologic agents is recommended by current treatment…
Abstract Number: 2416 • 2014 ACR/ARHP Annual Meeting
Do Patterns of Joint Swelling or Tenderness in Rheumatoid Arthritis Patients Impact Disease Activity Outcomes and Pain? Implications for Clinical Practice
Regan Arendse¹, John Kelsall², J. Antonio Avina-Zubieta³, Philip Baer⁴, Erica Weinberg⁴, Jude Rodrigues⁵, Algis Jovaisas⁶, Isabelle Fortin⁷, Maqbool Sheriff⁸, Majed M. Khraishi⁹, Emmanouil Rampakakis¹⁰, John S. Sampalis¹⁰, Francois Nantel¹¹, Susan Otawa¹² and Allen J Lehman¹², ¹University of Saskatchewan, Saskatoon, SK, Canada, ²The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Private Practice, Scarborough, ON, Canada, ⁵Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁶194 Main Street, University of Ottawa, Ottawa, ON, Canada, ⁷Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁸Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁹Nexus Clinical Research, Memorial University of Newfoundland, St Johns, NF, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose This analysis aimed to describe the pattern of specific joint involvement (tender and/or swollen) pre- and post-TNFi treatment and the impact of specific joint…
Abstract Number: 2417 • 2014 ACR/ARHP Annual Meeting
Is Remission Really Achievable in EARLY Rheumatoid Arthritis?
Olga Addimanda¹, Pierluigi Macchioni², Andrea Caruso¹, Niccolò Possemato¹, Mariagrazia Catanoso¹ and Carlo Salvarani², ¹S.C. Reumatologia, Arcispedale Santa Maria Nuova, I.R.C.C.S., Reggio Emilia, Italy, ²Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy
Background/Purpose: : to stress the need of routine use of US imaging in treat to target strategies aiming to achieve remission in early rheumatoid arthritis.…
Abstract Number: 2418 • 2014 ACR/ARHP Annual Meeting
Treatment Pattern and Direct Cost of Biologics for Rheumatoid Arthritis Patients: A Real-World Analysis of Nationwide Japanese Claims Data
Naonobu Sugiyama M.D., Ph.D¹, Tatsunori Murata, M.S.², Yosuke Morishima³, Yuri Fukuma⁴, Yoshiyuki Shibasaki⁴ and Lisa Marshall⁵, ¹Medical Affairs, Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ²Health Economics Research Group, CRECON Research and Consulting Inc., Tokyo, Japan, ³RA & Inflammation Area Medical Affairs Department, Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ⁴Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ⁵Inflammation Immunology Disease Group, Pfizer Inc. Inflammation Immunology Disease Group, Collegeville, PA
Background/Purpose Biologics such as etanercept (ETN), adalimumab (ADA), infliximab (IFX) and tocilizumab (TCZ) have led dramatic improvement in the treatment of rheumatoid arthritis (RA), but…
Abstract Number: 2419 • 2014 ACR/ARHP Annual Meeting
Efficacy of Biologic Medications in Active Rheumatoid Arthritis: A Systematic Review
Lynden Roberts^1,2, Kathleen Tymms³, Julien de Jager⁴, Geoffrey Littlejohn⁵, Hedley Griffiths⁶, David Nicholls⁷, Paul Bird⁸, Jennifer Young⁹ and Jane Zochling¹⁰, ¹JCU Clinical School, Townsville, QLD, Australia, ²Monash Medical Centre, Clayton, VIC, Australia, ³Canberra Rheumatology, Canberra, ACT, Australia, ⁴Olser House, Southport, QLD, Australia, ⁵Rheumatology, Monash Medical Centre and Monash University, Clayton, VIC, Australia, ⁶Barwon Rheumatology Service, Geelong, VIC, Australia, ⁷Coast Joint Care, Maroochydore, QLD, Australia, ⁸Combined Rheumatology Practice, Sydney, NSW, Australia, ⁹4-10 Inman Road, Roche Products Pty Limited, Sydney, NSW, Australia, ¹⁰Department of Rheumatology, Menzies Research Institute Tasmania, Hobart, TAS, Australia
Background/Purpose: In the last decade, biologic medications have transformed the management of RA. The effectiveness of these medications has been reported in numerous randomized controlled…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].